AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05857813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program for the Education and Enrichment of Relational Skills (PEERS®)
Description: developed at the University of California, Los Angeles (E. A. Laugeson \& F. Frankel, 2010). This is a parent-assisted, manualized social skills training program that addresses crucial areas of social functioning for adolescents. Psycho-education and cognitive-behavioral therapy techniques are employed to help adolescents develop ecologically valid skills for making and maintaining friendships.
Study NCT05342168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Using a swallowed expanding sponge (Cytosponge TM) to obtain sampling of the esophageal musosa
Description: A gelatin capsule containing the collapsed mesh sponge is swallowed with an attached string fixed to the cheek. After 8 minutes the gelatin capsule will have dissolved and the expanded soft mesh sponge can be with drawn sampling the surface of the esophagus on the way out. The sponge then will be spun and the supernant fixed, processed and stained.
Study NCT06212141 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisCalor Bulk,VOCO,Germany
Description: It was placed class II restorations.Before applying it, a 37% orthophosphoric acid will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin. Then, cavity will be rinsed with pressurized air and water for 15 sec. and Futura Bond U adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Then light air pressure will be applied for 5 sec., and then polymerization will be carried out for 10 sec. using LED light.~When it comes to the application of VisCalor , the VisCalor Gun , heating device will be used. A disposable composite capsule will be placed into the device, and it will be heated by selecting program 1 (65°C) for 30 sec. The material will remain hot for 2.5 min.~The nozzle of the capsule on the gun will be directly applied to the deepest part of the cavity, ensuring that the material is placed from bottom to top without exceeding 4 mm. Polymerization will be carried out with LED for 10 sec.
Study NCT06212141 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Admira Fusion x-tra,VOCO,Germany
Description: Admira Fusion x-tra composite resin was placed class II restorations. Before applying it an orthophosphoric acid with a concentration of 37% will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin. Then, cavity will be rinsed with pressurized air and water for 20 sec. And Futura Bond U adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Following the manufacturer's recommendations, light air pressure will be applied for 5 sec, and then polymerization will be carried out for 10 sec. using LED light with a power of 1200 mW/cm².~Afterwards bulk-fill composite will be placed in the cavity, ensuring that each layer does not exceed 4 mm, and appropriate occlusal shaping will be performed. Polymerization will be carried out with LED light for 20 seconds.
Study NCT06212141 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filtek One Bulk,3M,Germany
Description: Filtek One Bulk composite resin was placed class II restorations. Before applyingthe material, a 37% orthophosphoric acid will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin, followed by rinsing the cavity with pressurized air and water for 20 sec.Then , adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Following the manufacturer's recommendations, light air pressure will be applied for 5 sec, and then polymerization will be carried out for 10 sec using LED light .~Afterwards, bulk-fill composite will be placed in the cavity, ensuring that each layer does not exceed 4 mm, and appropriate occlusal shaping will be performed. Polymerization will be carried out with LED light at a power of 1200 mW/cm² for 10 sec from all directions, following the manufacturer's recommendations.
Study NCT05919446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Description: Each session in the ACT group will include the first hour of ACT intervention followed by 1 hour of back exercise class. The ACT group will be led by a trained ACT counsellor and a trained exercise trainer.
Study NCT05919446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: back exercise
Description: The control group will undergo 1 hour of back exercise class, while the control group will be led by a trained exercise trainer.
Study NCT05919446 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: back exercise
Description: The control group will undergo 1 hour of back exercise class, while the control group will be led by a trained exercise trainer.
Study NCT06345495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given by PO
Study NCT06345495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Description: Given by Transplant
Study NCT06345495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Given by PO
Study NCT06345495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Given by PO
Study NCT06345495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given by IV
Study NCT06345495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Given by IV
Study NCT06345495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV
Study NCT06345495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV
Study NCT06345495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given by IV
Study NCT06345495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given by IV or PO
Study NCT06173258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Water exchange alone
Description: During the insertion phase of water exchange colonoscopy, the air pump will be turned off, while the colon will be irrigated with warm-to-touch water using a flushing pump. The water exchange approach involves the simultaneous infusion of water to facilitate luminal expansion and suction of unclean water during insertion. Upon reaching the cecum, where most of the water is suctioned to collapse the cecal lumen, the air pump will be opened. Withdrawal from the cecum will begin in the left lateral position. Similar withdrawal techniques with adequate luminal distention and comprehensive examination behind the folds will be emphasized. Any position change away from the original left lateral position in any colon segment during the withdrawal phase will be recorded. Tandem examination of specific colon segments, including the right colon, either in the standard modality or retroflexion, is prohibited.
Study NCT06173258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water exchange alone
Description: During the insertion phase of water exchange colonoscopy, the air pump will be turned off, while the colon will be irrigated with warm-to-touch water using a flushing pump. The water exchange approach involves the simultaneous infusion of water to facilitate luminal expansion and suction of unclean water during insertion. Upon reaching the cecum, where most of the water is suctioned to collapse the cecal lumen, the air pump will be opened. Withdrawal from the cecum will begin in the left lateral position. Similar withdrawal techniques with adequate luminal distention and comprehensive examination behind the folds will be emphasized. Any position change away from the original left lateral position in any colon segment during the withdrawal phase will be recorded. Tandem examination of specific colon segments, including the right colon, either in the standard modality or retroflexion, is prohibited.
Study NCT06173258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Water exchange plus Artificial Intelligence (AI)
Description: Similar water exchange technique as the active comparator will be employed during insertion. Similar withdrawal inspection techniques as the active comparator will be used. During withdrawal phase, commercially available AI system (GI Genius, Medtronic, USA; CAD-EYE, Fujifilm, EU and Taiwan; Endo-AID, Olympus, EU and Taiwan) will be activated, providing a bounding box as output any time a lesion that is suspected to be a polyp is recognized by the AI device. False positive activation is defined as the identification by AI systems of an area during the withdrawal phase that is not deemed to be a colorectal lesion after re-examination by the colonoscopist. Real-time flagging of FP activation will be recorded by investigators and study staff.
Study NCT06173258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water exchange plus Artificial Intelligence (AI)
Description: Similar water exchange technique as the active comparator will be employed during insertion. Similar withdrawal inspection techniques as the active comparator will be used. During withdrawal phase, commercially available AI system (GI Genius, Medtronic, USA; CAD-EYE, Fujifilm, EU and Taiwan; Endo-AID, Olympus, EU and Taiwan) will be activated, providing a bounding box as output any time a lesion that is suspected to be a polyp is recognized by the AI device. False positive activation is defined as the identification by AI systems of an area during the withdrawal phase that is not deemed to be a colorectal lesion after re-examination by the colonoscopist. Real-time flagging of FP activation will be recorded by investigators and study staff.
Study NCT05276310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-002
Description: IMC-002 blocks the interaction between CD47 and SIRPα.
Study NCT04567355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Migraine Manager
Description: Answers provided during the online assessment will result in certain intervention recommendations. Once assessments are completed, a treatment plan will be automatically generated for patient and parent guidance.
Study NCT05908799 — intervention group
Intervention type: DRUG
Intervention: Pembrolizumab + Pemetrexed-Platinum
Description: Medication records in EHR database used to define exposure group
Study NCT05908799 — intervention group
Intervention type: DRUG
Intervention: Pemetrexed-Platinum
Description: Medication records in EHR database used to define comparator group
Study NCT05573191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The experimental group was injected with lidocaine 1.5mg/kg, and propofol was pumped intravenously at 90s after lidocaine injection.The dose of propofol was further set according to groups. The heart rate, mean arterial pressure, pulse oxygen saturation and NTI values of subjects were recorded in tne basic state,during the 90s after lidocaine administration, 60s after propofol administration and consciousness loss.The control group simply replaced lidocaine with equal volume normal saline
Study NCT05573191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline
Study NCT06512961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Flossing
Description: Tissue Flossing ia a elastic band that when applied exerts an external pressure above or below a muscle or joint of the extremities.
Study NCT06512961 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Flow Restriction Cuff
Description: Inflatable device that exerts an external pressure above a muscle or joint of the extremities.
Study NCT06512961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training Protocol
Description: The upper limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 15weeks, with 3 training sessions per week, with a day break between sessions.
Study NCT06512961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training Protocol
Description: The upper limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 15weeks, with 3 training sessions per week, with a day break between sessions.
Study NCT06635785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI-081
Description: AI-081 is a humanized monoclonal antibody with a silenced Fc targeting PD-1 and VEGF.
Study NCT06258668 — intervention group
Intervention type: DRUG
Intervention: Deucravacitinib
Description: As per product label
Study NCT06211907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Postoperative intraocular tamponade
Description: Flushing the eye cavity with a tamponade at the end of surgery
Study NCT06211907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative intraocular tamponade
Description: Flushing the eye cavity with a tamponade at the end of surgery
Study NCT05371288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)
Description: Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.
Study NCT05371288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)
Description: Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.
Study NCT05408559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane
Description: Caplets containing SFN-rich broccoli sprout extracts or placebo caplets containing microcrystalline cellulose will be obtained from from Nutramax Labs.
Study NCT04500613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Erector Spinae Plane Block with bupivacaine and dexamethasone
Description: Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures. Dexamethasone is a corticosteroid that reduces inflammation.
Study NCT04500613 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No bilateral Erector Spinae Plane Block (no bupivacaine and no dexamethasone)
Description: Patients who are randomized to this group will not receive a bilateral erector spinae plane block
Study NCT06020716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate 400 Mg-57 Mg/5 mL Oral Powder for Reconstitution
Description: Three times daily
Study NCT05408559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulforaphane
Description: Caplets containing SFN-rich broccoli sprout extracts or placebo caplets containing microcrystalline cellulose will be obtained from from Nutramax Labs.
Study NCT05099575 — intervention group
Intervention type: DRUG
Intervention: Syntocinon, papal, misotac
Description: Using different drugs to prevent atonic PPH during CD in high risk group
Study NCT05626517 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ocular Imaging
Description: The retinal photography will be acquired from macula-centre and an optic-disc centre for both left and right eye after their cardiac assessment. Patient will be required to focus at a target inside the machine for approximately 5 to 10 seconds, with a flash followed at the end when eye image is captured. Based on patients' eye conditions, additional or less images may be taken. This allows a snapshot of both retinal and coronary vessels at a single point in time, no mydriatic drops will be used. Participants will be given the option to undergo mydriatic photographs of the retina at SNEC/SERI depending on participant eye condition. For mydriatic photograph, images will be obtained after pupil dilation and graded for presence and severity of diabetic retinopathy according to the modified ETDRS system and other retinal abnormalities by trained graders.
Study NCT05626517 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: 3 to 4 questionnaires will be administered (i.e. EQ5D, International Index of Erectile Function, Pittsburgh Sleep Quality Index, General Questionnaire) to investigate the correlation between clinical characteristics, lifestyle (eg. exercise, sleep, erectile dysfunction) and diet to retinal and coronary vasculature and outcomes.Only male patients who are literate in English language will be invited to complete the International Index of Erectile Function (IIEF) questionnaire. Participants have the option to not complete the whole IIEF questionnaire or some of the questions if they are not comfortable with answering those questions.
Study NCT04955002 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06020716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three times daily
Study NCT06020716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Three times daily
Study NCT05295030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breast milk
Description: Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
Study NCT04296019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Maintenance therapy with fruquintinib ( 5 mg qd for 3 consecutive weeks, followed by discontinuation for 1 week).
Study NCT06182462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: The experimental group will receive a VR video game called DREAM DENTAL designed specifically for this study. Pharmaceutical treatment during the procedure such as the use of injected local anesthesia will be used if the procedure requires. Children will be able to play for the entire duration of the dental procedure. The VR video game aims at reducing anxiety in children aged 6 to 17 years old by means of immersive distraction. The VR headset offers children with the ability of viewing the game they are playing in real time while simultaneously obstructing the partial view they would normally have of the procedure. In the event of non-cooperation during the appointment, any retake or re-scheduling appointments will be compiled by the research assistant or resident dentist. One parent will be allowed in the room during the dental procedure and their presence will be recorded.
Study NCT06182462 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Clinic's Standard Treatment
Description: The control group will only receive a care-as-usual approach. This includes viewing cartoons on a muted mounted television set and the use of pharmaceutical treatment during the procedure such as the use of injected local anesthesia, according to the procedure. In the event of non-cooperation during the appointment, any retake or re-scheduling appointments will be compiled by the research assistant. One parent will be permitted to be present in the room during the procedure as part of the clinic's usual protocol and their presence will be recorded. Children allocated to the control group will be offered the possibility to try the VR game after the study period if they choose to do so.
Study NCT05147688 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study NCT06533878 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HY-209
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg
Study NCT06533878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HY-209
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg
Study NCT05295030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kieember Infant formula, Ruibuen®
Description: Kieember Infant formula, Ruibuen®: a type of Phase I infant formula for 0-6 month infants, with a trademark of Ruibuen®. The formula is characterized by (1) OPO structured lipid of the third generation; and (2) Breast Milk Simulated complete structured lipid UPU. It was produced by Yashili New Zealand Dairy Co., Limited
Study NCT05295030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yashili Infant formula, Ruibuen®
Description: Yashili Infant formula, Ruibuen®: a type of Phase I infant formula for 0-6 month infants, with a trademark of Ruibuen®. The formula is characterized by(1) lactoferrin and(2) lutein . It was produced by Yashili International Holdings Ltd.,China
Study NCT06533878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HY-209 placebo
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg
Study NCT06043817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STX-721 (Escalated)
Description: STX-721 dose will be escalated per cBLRM-design.
Study NCT06043817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STX-721 (2 doses)
Description: Participants will receive STX-721 at one of two doses.
Study NCT06043817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STX-721 (RP2D)
Description: Participants will receive the RP2D of STX-721.
Study NCT06119217 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030, nab-paclitaxel and gemcitabine
Description: Dose and schedule per protocol
Study NCT06119217 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030, budigalimab, nab-paclitaxel and gemcitabine
Description: Dose and schedule per protocol
Study NCT06119217 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel and gemcitabine
Description: Dose and schedule per protocol
Study NCT04970914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
Study NCT04970914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab 200 mg administered intravenously every 3 weeks.